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Purpose: Differentiating significant cancer from insignificant cancer is a major challenge in active surveillance (AS) for prostate 
cancer. We evaluated whether the apparent diffusion coefficient (ADC) grade from 3-T diffusion-weighted magnetic resonance 
imaging (DW-MRI) is useful to exclude men with unfavorable pathological features from men meeting current AS eligibility criteria. 
Methods: Among patients who underwent radical prostatectomy, 117 potential AS candidates defined according to 2013 European 
Association of Urology guidelines who had undergone preoperative 3-T DW-MRI were included. A blinded uro-radiologist graded the 
level of suspicion from the ADC map using the Likert scale from 1 to 5. The rate of unfavorable pathological features was evaluated 
according to ADC grade. Unfavorable pathological features were defined as non–organ-confined disease or pathological Gleason 
score ≥7 (4+3). The associations between unfavorable pathological features and clinical variables including ADC grade ( >3 vs. ≤3) 
were evaluated using logistic regression analysis. 
Results: The rates of unfavorable pathological features were 0.0% (0/14), 2.9% (1/34), 5.4% (2/37), 25.0% (6/24), and 37.5% (3/8) from 
grades 1 to 5 (P=0.002). The predictive accuracy was as high as 0.804. The rates were significantly different between low (≤3, 3.5%) 
and high ( >3, 28.1%, P<0.001) grades. The sensitivity, specificity, and positive and negative predictive values were 75.0%, 78.1%, 
28.1%, and 96.5%. ADC grade (odds ratio [OR], 10.696; 95% confidence interval [CI], 2.675–42.773) was significantly associated with 
unfavorable pathological features, even after adjusting for other variables (OR, 11.274; 95% CI, 2.622–48.471). 
Conclusions: ADC grade from 3-T DW-MRI is useful to predict men with unfavorable pathologic features from AS candidates. 
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INTRODUCTION
The chief treatment for localized prostate cancer (PC), even 
very low-risk disease, remains radical prostatectomy (RP) [1,2]. 
However, autopsy studies have demonstrated that 60%–70% 
of elderly men have histological PC [3], although only one-
third of them are clinically diagnosed before death [4]. Fur-
thermore, from 2.3% to 25% of unselected PC cases may have 
insignificant pathological features after surgery [5]. Thus, over-
treatment is currently a major concern for low-risk localized 
PC. Publication of the PIVOT trial in particular, has amplified 
this issue, because RP did not significantly improve overall or 
disease specific survival compared with observation in the 
PIVOT trial [6]. 
 Active surveillance (AS) is an attempt to reduce such over-
treatment. Early series of AS demonstrated excellent cancer-
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inition. Of these, 117 patients underwent 3-T multiparametric 
prostate MRI and were included in the final analysis.
3. MRI protocol and ADC grading 
All MRI examinations were performed after biopsy, usually 2 
to 6 weeks later. MR images were taken using a 3.0-T MR sys-
tem (Intera Achieva 3.0T, Philips Medical Systems, Best, The 
Netherlands) equipped with a phased-array cardiac 6-chan-
nel coil. In accordance with the recent guideline for prostate 
MR [13], we did not use an endorectal coil. All patients were 
injected with 20 mg butylscopolamine (Buscopan, Boehringer 
Ingelheim Pharma, Ingelheim, Germany) intramuscularly to 
suppress bowel peristalsis 30 minutes before imaging. Axial 
DW images were acquired using single-shot echo planar im-
aging. Scan parameters were as follows: TR, 2,500–3,000 ms; 
TE, 56–65 ms; slice thickness, 3 mm; interslice gap, 1 mm; 
field of view, 180 mm × 180 mm; matrix, 92 × 90; and number 
of excitations, 10. Diffusion encoding gradients were applied 
as a bipolar pair at b-values 0 and 1,000 s/mm2. ADC maps 
were automatically generated on a pixel-by-pixel basis. 
 An experienced uro-radiologist (S.I.H.), who was blinded 
to all clinical variables including pathological outcome, inde-
pendently graded the level of suspicion for clinically signifi-
cant cancer from ADC mapping images using the Likert scale 
from 1 to 5 as follows: grade 1, highly unlikely to be present; 
grade 2, unlikely to be present; grade 3, equivocal; grade 4, 
likely to be present; and grade 5, highly likely to be present 
specific and overall survival; however, one-third of patients 
required definitive treatment during a median 80 months or 
shorter follow-ups [2,7]. Thus, around one-third of patients 
might not be offered appropriate treatment at the proper 
time. Furthermore, longer-term oncological outcomes and 
quality of life are still unclear. Thus, the major challenge of 
differentiating those men who have significant cancer from 
those with insignificant cancer remains unresolved. 
 Recent reports suggest an emerging role for multiparamet-
ric magnetic resonance imaging (MRI) in PC diagnosis [8]. In 
particular, diffusion-weighted (DW)-MRI has been the focus 
of interest for its ability to identify aggressive cancer with 
higher Gleason score [9-12]. However, little is known regarding 
the role of DW-MRI in selecting PC patients for AS. Thus, we 
evaluated whether the apparent diffusion coefficient (ADC) 
grade determined with 3-T DW-MRI is useful for excluding 
men with unfavorable pathological features from current AS 
candidates. 
 
MATERIALS AND METHODS
1. Ethics statement
This study was approved by the Institutional Review Board 
(IRB) of Seoul National University Bundang Hospital (Seong-
nam, Republic of Korea). The approval number is B-1307/212-
109.
2. Patients 
We retrospectively reviewed the patients who underwent 
RP from January 2008 through April 2013 in Seoul National 
University Bundang Hospital. The eligibility criteria were AS 
candidates defined according to 2013 European Association 
of Urology guidelines (clinical stage T1c-T2a, prostate-specific 
antigen [PSA]≤10 ng/mL, biopsy Gleason score≤6 [at least 10 
cores], ≤2 positive cores, ≤50% cancer involvement in each 
core) [2], who had undergone preoperative 3-T multiparamet-
ric prostate MRI at our institution. We conducted multipara-
metric prostate MRI as a routine preoperative evaluation for 
RP. Almost all patients underwent either 1.5-T or 3-T MRI, and 
selection of magnetic field strength was determined not by 
clinical parameters but by schedule of the test. Men who had 
undergone any kind of neoadjuvant treatment or prior pros-
tate surgery were excluded, because these interventions could 
affect the MRI reading and pathological outcome. 
 Among 1,377 men treated with RP during the study period, 
25 and 14 patients were excluded because of neoadjuvant 
therapy and prior prostate surgery, respectively, and 237 pa-
tients met AS candidate eligibility according to the above def-
Fig. 1. Axial apparent diffusion coefficient map shows focal low 
signal intensity nodule (arrow) at right peripheral zone, which 
was graded 5.
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were compared. To evaluate the diagnostic value, we also 
calculated sensitivity, specificity, and positive and negative 
predictive values. 
 The associations between the unfavorable pathological 
features and clinical stage (T2a vs. T1c), PSA level, PSA den-
sity (≥0.15 vs. <0.15), positive core number (2 vs. 1), maximal 
percentage of cancer involvement in cores, and ADC grade 
( > 3 vs. ≤ 3) were evaluated using logistic regression analysis. 
To adjust for other significant variables, we constructed a 
multivariate logistic regression model using ADC grade ( > 3 
vs. ≤ 3) and the other significant variables by univariate logis-
tic regression analysis. To evaluate the additive effect of ADC 
grade on other variables, we also constructed a multivariable 
logistic regression model without ADC grade ( > 3 vs. ≤ 3) and 
then compared the 2 AUCs.  
 The data are expressed as the mean ± standard deviation of 
the mean. If needed, the range of values is also presented. P 
values of < 0.05 were considered to be statistically significant. 
RESULTS
The basic characteristics of the 117 patients are shown in 
Table 1. No seminal vesicle invasion or lymph node metastasis 
occurred in the cohort. Other key pathological outcomes ac-
cording to ADC grade are summarized in Table 2. Extrapros-
tatic extension, positive surgical margin, and unfavorable 
pathological features significantly differed between grades. 
However, no insignificant cancer was observed in ADC grade-5 
patients, and no unfavorable pathological features were ob-
served in ADC grade-1 patients. 
 The predictive accuracy measured by AUC was as high as 
0.804 (95% confidence interval [CI], 0.680–0.928) (Fig. 2). The 
rate of unfavorable pathological features significantly dif-
fered between low ( ≤ 3) and high ( > 3) grades (3.5% vs. 28.1%, 
P< 0.001). With this cutoff point ( > 3) for grade, the sensitivity, 
specificity, and positive and negative predictive values were 
75.0%, 78.1%, 28.1%, and 96.5%, respectively. 
(Fig. 1) [14]. No T1 or T2-weighted images were used for grad-
ing the level of suspicion.  
4. Outcome measurements and statistical analysis 
Several key pathological features were evaluated according to 
the ADC grade. The evaluated outcomes included extrapros-
tatic extension, seminal vesicle invasion, lymph node metas-
tasis, positive surgical margin, pathological Gleason score≥7 
(any score combination), pathological Gleason score ≥ 7 (4+3), 
tumor volume < 0.5 mL, insignificant cancer, and unfavorable 
pathological features. Insignificant cancer was defined by the 
Stamey criteria (organ-confined, Gleason score ≤ 6, and tu-
mor volume < 0.5 mL) [5]. Unfavorable pathological features 
were defined as nonorgan confined disease or pathological 
Gleason score ≥ 7 (4+3) regardless with surgical margin status. 
We focused our analysis to evaluate the association between 
ADC grade and unfavorable pathological features. The pre-
dictive accuracy for unfavorable pathological features was as-
sessed using the area under the receiver operating character-
istic curve (AUC). After dividing the low- ( ≤ 3) and high-grade 
( > 3) cases, the rates of unfavorable pathological features 
Table 1. Basic characteristics of the patients
Characteristic Value
Age (yr) 65.3±6.4 (43–76)
Clinical stage
   cT1 94 (80.3)
   cT2a 23 (19.7)
PSA (ng/mL) 5.5±2.0 (1.7–9.9)
PSA density (ng/mL/mL) 0.15±0.06 (0.05–0.46)
PSA density
   <0.15 68 (58.1)
   ≥0.15 49 (41.9)
Positive biopsy cores
   1 81 (69.2)
   2 36 (30.8)
Maximum % of core 14.9±10.3 (1.3–46.7)
Values are presented as mean±standard deviation (range) or number (%).
PSA, prostate-specific antigen.
Table 2. Key pathological outcomes after radical prostatectomy according to ADC grade
ADC grade
Extraprostatic 
extension
Positive surgical 
margin
Pathologic 
Gleason≥7
Pathologic 
Gleason≥7 (4+3)
Tumor 
volume<0.5 mL
Insignificant 
cancer
Unfavorable 
pathologic features
1 (n=14, 12.0%) 0 (0) 0 (0) 7 (50.0) 0 (0) 2 (14.3) 2 (14.3) 0 (0)
2 (n=34, 29.1%) 1 (2.9) 1 (2.9) 21 (61.8) 0 (0) 6 (17.6) 4 (11.8) 1 (2.9)
3 (n=37, 31.6%) 1 (2.7) 2 (5.4) 20 (54.1) 1 (2.7) 10 (27.0) 8 (21.6) 2 (5.4)
4 (n=24, 20.5%) 4 (16.7) 3 (12.5) 16 (66.7) 2 (8.3) 6 (25.0) 4 (16.7) 6 (25.0)
5 (n=8, 6.8%) 3 (37.5) 4 (50.0) 7 (87.5) 1 (12.5) 1 (12.5) 0 (0) 3 (37.5)
P-value 0.003 <0.001 0.387 0.239 0.742 0.567 0.002
Values are presented as number (%).
ADC, apparent diffusion coefficient.
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 Positive core number (2 vs. 1, P=0.038), maximal percent-
age of cancer involvement in cores (P=0.024), and ADC grade 
( > 3 vs. ≤  3, P= 0.001) were significantly associated with unfa-
vorable pathological features by univariate logistic regression 
analyses (Table 3). Multivariate logistic regression models 
with or without ADC grade are shown in Table 3. After ad-
justing for other variables, ADC grade was still a significant 
predictor (odds ratio [OR], 11.274; 95% CI, 2.622–48.471, 
P= 0.001). Adding ADC grade led to an increase in AUC of 
0.130 compared with the multivariate logistic regression 
model without ADC grade (0.861 vs. 0.731).  
DISCUSSION
DW-MRI is a form of functional MRI derived from the move-
ment of hydrogen protons in water molecules. The ADC is cal-
culated by the distance of the movements, thus it is reversely 
correlated with tissue cellularity. Higher grade PC usually has 
higher cellularity and decreased extracellular space. There-
fore, ADC is decreased in cancerous tissue in the prostate [8]. 
The value of the ADC lies not only in its localization of PC but 
also its correlation with cancer aggressiveness [9]. Tumors 
with lower ADC values have been revealed as having larger 
tumor volume and higher Gleason score [11,12,15,16]. Based 
on these advantages, the clinical value of DW-MRI stands out 
among multiparametric MRI protocols. Many researchers are 
exploring its clinical implications for AS.
 In the Royal Marsden AS cohort, among 86 men who un-
derwent 1.5-T multiparametric MRI, tumorous ADC was 
significantly associated with both adverse repeat biopsy 
results (hazard ratio [HR], 1.3; 95% CI, 1.1–1.6) and time to 
definitive intervention (HR, 1.5; 95% CI, 1.2–1.8) [10]. These 
findings were confirmed by their similar prospective study 
[17]. The MR-PRIAS Collaboration Group performed a corre-
lation study of RP specimens with a small number of patients 
(n = 23) [9]. The participants were not AS candidates, but had 
biopsy Gleason scores ≤ 6. The authors concluded that 3-T 
DW-MRI could predict the presence of tumor components 
with Gleason score ≥ 4 in the final pathology assessment. 
Subsequently, they conducted a nested study within PRIAS, 
a prospective large-scale AS study [18]. They performed MRI-
guided biopsy using 3-T multiparametric MRI at the time of 
AS inclusion to re-stratify risk. Tumors with a higher Gleason 
score ( > 6) had significantly lower ADC values than those 
with lower Gleason score ( ≤ 6).
 Other trials using combinations of several multiparametric 
MRI protocols to select AS candidates have also been per-
formed. Most of them were tested in RP series of low-risk pa-
tients or at the time of AS inclusion with confirmatory biopsy 
[19-21]. However, this approach may not be widely applicable 
in daily practice.   
Table 3. Logistic regression analyses predicting unfavorable pathologic features
Variable
Univariate analyses Multivariate model 1 Multivariate model 2
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Clinical stage, T2a vs. T1c 0.800 (0.163–3.930) 0.783 - - - -
PSA (ng/mL) 0.950 (0.702–1.286) 0.740 - - - -
PSA density, ≥0.15 vs. <0.15 2.100 (0.625–7.058) 0.230 - - - -
Positive number cores, 2 vs. 1 3.669 (1.078–12.487) 0.038 2.597 (0.704–9.576) 0.152 3.328 (0.761–14.544) 0.110
Maximum % of cancer involvement in cores 1.062 (1.008–1.119) 0.024 1.048 (0.991–1.108) 0.099 1.036 (0.973–1.102) 0.270
ADC grade, >3 vs. ≤3 10.696 (2.675–42.773) 0.001 - - 11.274 (2.622–48.471) 0.001
AUC (95% CI) - - 0.731 (0.641–0.808) - 0.861 (0.785–0.918) -
AUC difference - - Reference - 0.130 -
CI, confidence interval; PSA, prostate-specific antigen; ADC, apparent diffusion coefficient.
Fig. 2. The receiver operating characteristic curve of apparent 
diffusion coefficient grade predicting unfavorable pathologic 
features. The area under the curve was 0.804 (95% confidence 
interval, 0.680–0.928).
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 Our present investigation was a correlation study between 
ADC grade and RP pathology in men who met AS eligibil-
ity. To our knowledge, this report is the first comprehensive 
pathological analysis of the value of ADC grade generated 
from 3-T DW-MRI in AS candidates. Higher resolution can 
be obtained with 3-T compared to 1.5-T MRI not only for 
conventional images but also for ADC maps due to its higher 
signal-to-noise ratio [13]. Transition from 1.5-T to 3-T MRI is 
a current trend for PC diagnosis. Thus, we selected a 3-T MRI 
protocol for homogeneity and future applicability. Someone 
can raise an issue of selection bias. However, multiparametric 
prostate MRI has been a routine evaluation before RP. And 
the selection between 1.5-T and 3-T was determined just by 
schedule of the test. Thus, allocation was almost random as-
signment, although it was not intended. Of 237 patients met 
AS candidate eligibility, 116 and 117 men underwent 1.5-
T and 3-T multiparametric prostate MRI, respectively in the 
present study. Four patients did not take prostate MRI in our 
institution because they underwent it before referral to our 
hospital. We graded ADC using the Likert scale rather than b-
value criteria. The ADC Likert scale may be subjective, but it 
is widely applicable in daily practice. Our findings also indi-
cated that ADC grade could help to select patients suitable for 
AS. Particularly, we focused on excluding inappropriate men 
who harbored unfavorable pathological features.    
 We defined unfavorable pathological features as nonorgan 
confined disease or pathological Gleason score ≥ 7 (4+3) to 
identify men who should definitely be excluded. The PIVOT 
trial demonstrated no definitive survival benefit of RP com-
pared to observation for men with localized PC [6]. RP was as-
sociated with survival benefit among men with PSA > 10 ng/
mL and possibly among those with intermediate- or high-risk 
tumor. Furthermore, recent data from AS series showed gen-
erally good performance [2,7]. Gleason score 7 (4+3) clearly 
differs from Gleason score 7 (3+4) and is similar to Gleason 
score 8 with respect to recurrence and PC-specific survival 
[22,23]. In our cohort, one patient had Gleason score ≥ 8. Al-
though many AS trials use biopsy Gleason grade 4 patterns as 
a trigger for definitive treatment, many Gleason 7 (3+4) cases 
are upgraded in RP specimens [24]. Thus, pathological Glea-
son score ≥ 7 (4+3) is a reasonable criterion for unfavorable 
features in RP specimens. 
 Our cohort was selected using current AS eligibility cri-
teria, and no patients demonstrated extremely unfavorable 
pathology, such as seminal vesicle invasion or lymph node 
metastasis. However, 9 (7.7%) experienced extraprostatic ex-
tension, and 71 (60.7%) had pathological Gleason score ≥ 7. 
When our definition of unfavorable pathological features was 
applied, 12 men (10.3%) were classified as unsuitable for AS. 
ADC grade was useful to exclude these unsuitable patients 
for AS. Its OR was more than 10 and better than preopera-
tive biopsy parameters both in univariate and multivariate 
analysis. Although positive predictive value was low, negative 
predictive value was very high. Thus, when ADC grade is low 
(e.g., ≤ 3), patients can comfortably undergo an AS protocol. 
Furthermore, we observed no cases of insignificant cancer 
among ADC grade-5 patients, and no unfavorable pathology 
was detected in ADC grade-1 patients. ADC grade markedly 
added value to conventional clinical information for selecting 
AS candidates, with an improvement in AUC of 0.130 (0.861 
vs. 0.731) (Table 3). By bearing in mind these characteristics, 
we can select AS patients with prudence. 
 In the present study, the rate of upgrading to pathological 
Gleason score ≥ 7 (60.7%) seems to be higher than other data. 
This Gleason upgrading in contemporary RP series is about 
35% [25], however it is higher in the patients who underwent 
RP following initial AS up to 55.2% [26]. We consider higher 
upgrading rate in the present study may be caused by the ag-
gressive phenotype of PC in Korean population than in West-
ern series [27,28]. Gleason score upgrading in surveillance 
candidate who actually underwent RP ranged from 41.6% to 
50.6% in other Korean cohort [29].
 Although the results of this study are clinically significant, it 
also has several limitations. It was a single-center, retrospec-
tive analysis. Thus someone may claim selection bias. How-
ever, AS was not a standard treatment in our institution and 
almost all of the very low-risk PC patients were undergone 
RP. Furthermore, almost all patients underwent prostate MRI, 
and selection of magnetic field strength was determined not 
by clinical parameters but by schedule of the test. Thus we 
consider that selection bias in the study is not significant. All 
MRI were taken after biopsy, thus it could be considerable 
limitation, even though ADC is not much affected by hemor-
rhage. As another limitation, we did not test using various AS 
criteria. However, the clinical contexts of the various criteria 
were similar. Our results warrant further multicenter large-
scale investigation or prospective study. In the long term, 
after ADC grade is incorporated into AS criteria, we should 
confirm how much percentage of AS-eligible patients who 
undergo definitive treatment will be decreased.
 In summary, ADC grade determined with 3-T DW-MRI is 
useful for predicting AS candidates with unfavorable patho-
logical features. This result should be confirmed by large-
scale multicenter studies or prospective clinical trials. Our 
finding suggests that incorporating ADC grade as a criterion 
for selecting candidates for AS among PC patients.  
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